37614-91-8

Basic information

• Product Name: 2-chloro-N-[4-(4-nitrophenyl)-1,3-thiazol-2-yl]acetamide
• Synonyms: 2-chloro-N-[4-(4-nitrophenyl)-1,3-thiazol-2-yl]acetamide
• CAS NO: 37614-91-8
• Molecular Weight: 297.722
• Mol File: 37614-91-8.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 2-chloro-N-[4-(4-nitrophenyl)-1,3-thiazol-2-yl]acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-N-[4-(4-nitrophenyl)-1,3-thiazol-2-yl]acetamide(37614-91-8)
• EPA Substance Registry System: 2-chloro-N-[4-(4-nitrophenyl)-1,3-thiazol-2-yl]acetamide(37614-91-8)

Safety Data

• Hazardous Substances Data: 37614-91-8(Hazardous Substances Data)

Upstream product

• 2104-09-8 4-(4-nitro-phenyl)-thiazol-2-ylamine 
• 541-88-8 Chloroacetic anhydride 
• 99-81-0 4-Nitrophenacyl bromide 
• 100-19-6 (4-nitrophenyl)ethanone 
• 34006-49-0 2-chloro-1-(4-nitrophenyl)ethanone 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 91402-03-8 2-Isobutylamino-N-[4-(4-nitro-phenyl)-thiazol-2-yl]-acetamide 
• 406470-92-6 2-((2-((4-(4-nitrophenyl)thiazol-2-yl)amino)-2-oxoethyl)thio)acetic acid 

Relevant articles and documents

Synthesis and biological evaluation of 2,4-disubstituted thiazole amide derivatives as anticancer agent

A series of novel 2,4-disubstituted thiazole amide derivatives were synthesized, and their antiproliferative activities were tested. Some of these compounds displayed good antiproliferative activity, especially for HT29 cell. Among these compounds, compound 5b inhibits A549, HeLa, HT29 and Karpas299 cells with IC50 values of 8.64, 6.05, 0.63 and 13.87?μM, respectively. The western blot analysis and docking study provide important clues for further optimization of compound 5b as a potential c-Met inhibitor.

Β - secretase enzyme has the function of inhibiting compound, the preparation of the compounds and use thereof

The invention discloses a compound capable of inhibiting beta-secretase, and a preparation method and application thereof. The structure of the compound is shown in a formula I, formula II or formula III as described in the specification. In the formula I, X is S or NH; R1 is selected from hydrogen and nitro group; R2 and R4 are same or different and independently selected from the group consisting of hydrogen, halogen, nitro group and substituted aryl group; R3 is selected from the group consisting of hydrogen, nitro group, straight-chain and branched-chain alkyl and substituted alkyl groups with a carbon number of 1 to 4, alkylamino or alkyloxy group with a carbon number of 1 to 4 and alkylamido group with a carbon number of 1 to 4; R is located at position 2, 3 or 4 of a benzene ring and selected from the group consisting of hydrogen, straight-chain and branched-chain alkyl and substituted alkyl groups with a carbon number of 1 to 4, alkylamino or alkyloxy group with a carbon number of 1 to 4 and alkylamido group with a carbon number of 1 to 4. In the formula II, R is selected from different substituted aryl groups. In the formula III, R is selected from hydrogen or cyano group. Experiments prove that the compound provided by the invention has good beta-secretase inhibitory activity and has wide application values as a beta-secretase inhibitor.

2-Substituted-thio-N-(4-substituted-thiazol/1H-imidazol-2-yl)acetamides as BACE1 inhibitors: Synthesis, biological evaluation and?docking studies

In this work, a series of 2-substituted-thio-N-(4-substituted-thiazol/1H-imidazol-2-yl)acetamide derivatives were developed as β-secretase (BACE-1) inhibitors. Supported by docking study, a small library of derivatives were designed, synthesized and biologically evaluated in vitro. In addition, the selected compounds were tested with affinity (KD) towards BACE-1, blood brain barrier (BBB) permeability and cytotoxicity. The studies revealed that the most potent analog 41 (IC50 = 4.6 μM) with high predicted BBB permeability and low cellular cytotoxicity, could serve as a good lead structure for further optimization.